Description:
Background:
- One way to treat certain cancers of the blood and immune system is to give a patient
stem cells from the bone marrow of a donor whose genes are very similar but not
identical to the patients. One problem with these transplants is that the new immune
cells may not work as well in the recipient as they did in the donor. The result may be
that the immune system will not work as well. This can increase the risk of severe
infections and other complications.
- Researchers are studying the use of drugs that lower hormone levels and may allow the
immune system to recover in a way that improves white blood cell function. In this study
they will be looking at the drug leuprolide, a drug that lowers estrogen or testosterone
levels, to see if it might improve the function of the newly transplanted cells.
Objectives:
- To determine whether leuprolide improves immune system function after bone marrow
transplant from a donor with similarities in their immune cells (matched to each other).
- To evaluate the effectiveness of a nuclear medicine test with a radiotracer drug
3-deoxy-3 18F-fluorothymidine (FLT) in imaging studies. FLT will be used to image the
immune system function in patients who have received bone marrow from the donor.
Eligibility:
- People between 15 (or as young as 9 in those who have gone through puberty) and 55 years
of age. These patients must have acute myelogenous leukemia, acute lymphocytic leukemia,
high-risk myelodysplastic syndrome, chronic myelomonocytic leukemia, or chronic myeloid
leukemia. They must also be eligible for a bone marrow transplant.
- Genetically similar donors for the patients who are eligible for a transplant.
Design:
- People taking part in the study will be screened with a physical examination, medical
history, blood and urine tests, and imaging studies. Patients who are not in remission
or who require a bone marrow donor search may receive chemotherapy first.
- Donors will provide bone marrow for transplant according to standard bone marrow
transplant (BMT) procedures.
- All women and half of the men will receive regular leuprolide doses 2 weeks before BMT
to suppress hormone function.
- All recipients will receive 4 days of radiation followed by 2-4 days of chemotherapy
before the bone marrow transplant (depending on age). Recipients will also receive other
drugs to prevent transplant rejection and other complications of transplantation.
- Recipients will be monitored in the hospital for 4 weeks after transplant with blood
tests and other studies.
- Some recipients will have an imaging study with FLT during the protocol. These imaging
studies will take place before the transplant, on days 5 and 28 after transplant, and at
a later time to be determined by the study researchers.
- Following discharge, participants will be monitored closely for up to 6 months, with
regular but less frequent followup visits for at least 5 years. Study-related
medications, including vaccinations for the new immune system, will be provided by the
National Institutes of Health during the hospital stay and after discharge.
Title
- Brief Title: Pilot Study of Leuprolide to Improve Immune Function After Allogeneic Bone Marrow Transplantation
- Official Title: Multi-Institutional Prospective Pilot Study of Lupron to Enhance Lymphocyte Immune Reconstitution Following Allogeneic Bone Marrow Transplantation in Post-Pubertal Children and Adults With Molecular Imaging Evaluation
Clinical Trial IDs
- ORG STUDY ID:
110136
- SECONDARY ID:
11-C-0136
- NCT ID:
NCT01338987
Conditions
- Myelodysplastic Syndrome
- Acute Lymphocytic Leukemia
- Acute Myelogenous Leukemia
- Chronic Myelogenous Leukemia
- Chronic Myelomonocytic Leukemia
Interventions
Drug | Synonyms | Arms |
---|
Leuprolide | Lupron | Arm1 First Transplt/males/leuprolide/+/-FLT Imaging |
18F FLT | [18F]fluorothymidine | Arm1 First Transplt/males/leuprolide/+/-FLT Imaging |
Cyclophosphamide | Cytoxan | Arm1 First Transplt/males/leuprolide/+/-FLT Imaging |
Methotrexate | Trexall | Arm1 First Transplt/males/leuprolide/+/-FLT Imaging |
Tacrolimus | Prograf | Arm1 First Transplt/males/leuprolide/+/-FLT Imaging |
Busulfan | Busulfex | Arm4-Second Transplt/leuprolide and FLT Imaging |
Fludarabine | Fludara | Arm4-Second Transplt/leuprolide and FLT Imaging |
Purpose
Background:
- One way to treat certain cancers of the blood and immune system is to give a patient
stem cells from the bone marrow of a donor whose genes are very similar but not
identical to the patients. One problem with these transplants is that the new immune
cells may not work as well in the recipient as they did in the donor. The result may be
that the immune system will not work as well. This can increase the risk of severe
infections and other complications.
- Researchers are studying the use of drugs that lower hormone levels and may allow the
immune system to recover in a way that improves white blood cell function. In this study
they will be looking at the drug leuprolide, a drug that lowers estrogen or testosterone
levels, to see if it might improve the function of the newly transplanted cells.
Objectives:
- To determine whether leuprolide improves immune system function after bone marrow
transplant from a donor with similarities in their immune cells (matched to each other).
- To evaluate the effectiveness of a nuclear medicine test with a radiotracer drug
3-deoxy-3 18F-fluorothymidine (FLT) in imaging studies. FLT will be used to image the
immune system function in patients who have received bone marrow from the donor.
Eligibility:
- People between 15 (or as young as 9 in those who have gone through puberty) and 55 years
of age. These patients must have acute myelogenous leukemia, acute lymphocytic leukemia,
high-risk myelodysplastic syndrome, chronic myelomonocytic leukemia, or chronic myeloid
leukemia. They must also be eligible for a bone marrow transplant.
- Genetically similar donors for the patients who are eligible for a transplant.
Design:
- People taking part in the study will be screened with a physical examination, medical
history, blood and urine tests, and imaging studies. Patients who are not in remission
or who require a bone marrow donor search may receive chemotherapy first.
- Donors will provide bone marrow for transplant according to standard bone marrow
transplant (BMT) procedures.
- All women and half of the men will receive regular leuprolide doses 2 weeks before BMT
to suppress hormone function.
- All recipients will receive 4 days of radiation followed by 2-4 days of chemotherapy
before the bone marrow transplant (depending on age). Recipients will also receive other
drugs to prevent transplant rejection and other complications of transplantation.
- Recipients will be monitored in the hospital for 4 weeks after transplant with blood
tests and other studies.
- Some recipients will have an imaging study with FLT during the protocol. These imaging
studies will take place before the transplant, on days 5 and 28 after transplant, and at
a later time to be determined by the study researchers.
- Following discharge, participants will be monitored closely for up to 6 months, with
regular but less frequent followup visits for at least 5 years. Study-related
medications, including vaccinations for the new immune system, will be provided by the
National Institutes of Health during the hospital stay and after discharge.
Detailed Description
Background:
- Impaired lymphocyte immune reconstitution is associated with morbidity and mortality
following allogeneic bone marrow transplant (BMT).
- Data suggest that one of the limitations of immunity after BMT is the lack of thymus
recovery and proper B cell development.
- Androgen withdrawal has been shown to enhance T and B lymphopoiesis.
- Leuprolide is an approved, safe, gonadotropin releasing hormone (GnRH)
agonist/antagonist.
- Noninvasive imaging modalities to study immune reconstitution would be invaluable to
predict optimal or impaired immune recovery permitting early institution of therapies.
- FLT is 3-deoxy-3 18F-fluorothymidine, a radiolabeled thymidine analogue that illustrates
dividing hematopoietic cells and may predict immune recovery after allogeneic BMT.
- FLT has been used safely in patients who have received intensive chemotherapy.
Objectives:
- Primary: To determine if leuprolide improves B lymphocyte reconstitution after first
BMT.
- Primary: To assess whether 18F FLT positron emission tomography (PET)/computed
tomography (CT) could predict early engraftment/immune reconstitution in marrow and
thymus after allogeneic BMT.
- Primary: To assess safety of leuprolide after 2nd BMT evaluated in a separate arm.
Eligibility:
- Patients > 9 years old and pubertal and/or >15 year and less than or equal to 55 years,
with aggressive leukemia (Acute Myelogenous Leukemia (AML), myelodysplastic syndromes
(MDS) with high risk cytogenetics, Acute Lymphocytic Leukemia (ALL), CMML, certain CML)
requiring BMT will be enrolled at National Cancer Institute (NCI).
- At University of Oklahoma, Age > 17 years old and less than or equal to 55 years for
recipient.
- Patients > 4 and < 24 years with the above diseases will be enrolled at Children's
National Medical Center (CNMC).
Design:
- This is a prospective pilot study, the primary aims of which are: 1) to assess whether
leuprolide enhances lymphocyte recovery after first BMT, 2) whether FLT imaging can be
used to predict engraftment/immune reconstitution after first transplant, and 3) whether
leuprolide and FLT are tolerable for second HSCT.
- At NCI and Univ of Oklahoma, post-pubertal pediatric male patients (<18 years) will be
randomized to receive a 3 month (11.25 mg) injection and adult male patients will be
randomized to receive 4-month preparation of leuprolide (30 mg) or placebo two weeks
before the preparative regimen for first BMT. Women and all individuals undergoing 2nd
BMT will receive leuprolide at these doses per age and be evaluated in the treated
cohort. At Children's National Medical Center, the patients will not receive leuprolide
outside of the context of clinical care and will receive myeloablative BMT as per
standard of care with FLT imaging for engraftment as the only primary endpoint.
- A target of 68 evaluable adult patients will be enrolled on this trial, which may
necessitate up to 118 patients (118 donors) enrolled to reach this target at NCI and
University of Oklahoma. A total of 10 pediatric patients will be enrolled at Children's
National Medical Center for FLT imaging only. Sixteen patients will be enrolled to
undergo second BMT.
- At NCI, adults greater than 18 years old both female and adult male patients undergoing
2nd BMT will receive 4-month preparation of leuprolide (30 mg) two weeks before the
preparative regimen. All patients will undergo FLT imaging to evaluate whether this may
predict BMT response or failure (relapse). This will be a pilot arm of 16 patients
total.
- The planned length of this trial is 7 years with interim analyses at day 100 and day
365.
- Some of the patients are anticipated to be evaluated using FLT (to include only patients
needed for the immunological primary endpoint, not increasing total patient numbers). 23
adult NCI patients in total will undergo FLT PET/CT imaging on day -1, at day +5 or day
+9, at 4 weeks, and at a future point to include evidence of graft-versus-host disease
(GVHD) relapse, or immune recovery. An estimated 50 patients (including subset of the 23
patients undergoing serial scanning) will be imaged approximately at 1 year for
evaluation of thymus reconstitution. The total possible numbers will include no more
than 118 patients to achieve the 68 evaluable adults for the immunological primary
endpoint. However, all 23 FLT PET/CT imaged NCI patients will undergo a single 1 year
FLT for evaluation of thymus reconstitution. Up to 10 pediatric patients at CNMC will
undergo FLT PET/CT imaging on Day -1, day+9, and day +28 (if possible). Initial images
will be correlated with engraftment and other secondary endpoints.
Trial Arms
Name | Type | Description | Interventions |
---|
Arm1 First Transplt/males/leuprolide/+/-FLT Imaging | Active Comparator | Males randomized to leuprolide for first transplant.
[18F]fluorothymidine (FLT) imaging | - Leuprolide
- 18F FLT
- Cyclophosphamide
- Methotrexate
- Tacrolimus
|
Arm2 First Transplt/males/No Leuprolide/+/- FLT Imaging | Active Comparator | Males not receiving leuprolide for first transplant
[18F]fluorothymidine (FLT) imaging | - 18F FLT
- Cyclophosphamide
- Methotrexate
- Tacrolimus
|
Arm3 First Transplt/females/leuprolide+/- FLT Imaging | Experimental | Females receiving leuprolide for first transplant.
[18F]fluorothymidine (FLT) imaging | - 18F FLT
- Cyclophosphamide
- Methotrexate
- Tacrolimus
|
Arm4-Second Transplt/leuprolide and FLT Imaging | Experimental | Second transplant with leuprolide and [18F]fluorothymidine (FLT) imaging | - Leuprolide
- 18F FLT
- Cyclophosphamide
- Busulfan
- Fludarabine
|
Healthy Volunteer - Arm 5 | No Intervention | Healthy Volunteer | |
Eligibility Criteria
- ELIGIBILITY CRITERIA:
INCLUSION CRITERIA: TRANSPLANT RECIPIENT
1. At National Institutes of Health (NIH). Age greater than or equal to 15 years old
and/or greater than or equal to 9 years old and pubertal and less than or equal to 55
years for recipient. Pubertal is defined by: prior menses at any time (females),
documentation of clinical Tanner stage greater than 2 at some point pre-chemotherapy
or at the current visit. (At this point, sex steroids have been produced for a few
years which have driven initial pubertal development). Tanner 2 is defined as: breast
buds for females with coarse pubic hair, and coarse pubic hair and testes > 2.5cm for
males.
2. At Children's National Medical Center only: age > 4 years old and < 24.
3. At University of Oklahoma: Age greater than or equal to 17 years old and less than or
equal to 55 years for recipient.
4. A diagnosis of a hematologic malignancy for which stem cell transplant is standard of
care:
4.1. Acute Lymphocytic Leukemia (ALL)
Adult: (greater than or equal to 22 years) greater than or equal to compete remission 2
(CR2) OR complete remission 1 (CR1) with:
- Matched sibling donor for recipient treated on adult leukemia regimen
- t(9:22) or bcr-abl+; t(4:11), t(1:19), t(8:14), 11q23 (MLL rearrangements) complex
cytogenetics (5 or more chromosomal abnormalities), hypodiploidy (<44 chromosomes).
Note that patients with ALL blast crisis who emerge from chronic myeloid leukemia
(CML) are also eligible
- Primary induction failure, defined as failure to achieve CR with primary induction
chemotherapy
- High white blood cell (WBC) (>30,000 for B-cell ALL and >100,000 for T-cell ALL) at
diagnosis
- Persistence of minimal residual disease despite induction chemotherapy
Pediatric (< 22 years): greater than or equal to CR2 OR CR1 with high risk features
- Matched sibling donor for recipient treated on adult leukemia regimen
- Primary induction failure (M3 (>25% with greater 200 cells counted) marrow at day 29),
M2 (5-25% blasts with greater than 200 cells counted) bone marrow or minimal residual
disease (MRD) > 1% at day 29 who then fail at day 43 with either an M2 or M3 BM or MRD
> 1%
- Persistent leukemia and t(9;22) (MRD >1% day 29 or MRD > 0.01% end consolidation)
- 11q23 (MLL) rearrangements detected by cytogenetic or polymerase chain reaction (PCR)
at initial diagnosis who are slow early responders (M2/M3 at day 14 or MRD> 0.01% at
day 29)
- Extreme hypodiploidy (< 44 chromosomes or deoxyribonucleic acid (DNA) index of <0.81)
detected by cytogenetic/ploidy analysis
4.2 Acute Myelogenous Leukemia
Adult: (greater than or equal to 22 years) greater than or equal to CR2 OR CR1 with high
one of the following risk features
-Adverse or intermediate-risk cytogenetics including:
1. Normal cytogenetics
2. complex karyotype (>2 abnormalities)
3. inv (3) or t (3;3); t(11;19)(q23;p13.1); +13; -17/17p-; -18; -20; (t(6;9); t(6;11);
-7, 7q-; -5, 5q-; trisomy 8; t(3;5); t(9:11)(p22q23)
4. monosomy karyotype (presence of an autosomal monosomy in conjunction with at least one
other autosomal monosomy or structural abnormality.
5. Any other karyotype EXCEPT t(8;21), t(9;11), inv(16), or t (16;16), and M3 (17; 17)
unless ckit mutation present and then eligible.
6. AML emerging from CML (blast crisis) are eligible
-Primary induction failure, defined as failure to achieve CR with primary induction
chemotherapy
- Secondary AML, defined as AML related to antecedent myelodysplastic syndrome
(MDS), myeloproliferative neoplasms (MPN), or cytotoxic chemotherapy
- Hyperleukocytosis (White blood cell (WBC) > 100,000 at diagnosis)
- Mutations in the FMS-like tyrosine kinase 3 (FLT3) gene (FLT3-LM; FLT-ITDs)
- Bilineage or biphenotypic leukemias are high risk features and eligible.
Pediatric (< 22 years): greater than or equal to CR2 OR CR1 with a high risk feature
including:
-Primary induction failure (greater than or equal to 5% blasts in marrow after
induction)
- Persistent leukemia (>15% after first course of chemotherapy)
- Complex karyotype, monosomy 7, or -5/-5q, FLT3 ITD-AR (>0.4) EXCEPT if also
inv(16)/t(16;16), t(8,21)
- Normal cytogenetics or abnormal cytogenetics EXCEPT if also inv(16)/t(16;16),
t(8,21) are eligible for SIBLING transplant only
- Bilineage or biphenotypic leukemias are high risk features and eligible.
4.3. Myelodysplastic Syndrome Refractory Anemia with Excess Blasts (RAEB) 1 or 2;
cytogenetics showing complex karyotype (3 or more abnormalities), monosomy 7/del(7q),
or inv(3)/t(3q)/del(3q); or transfusion dependent.
4.4. Chronic Myelomonocytic Leukemia
4.5. Chronic Myelogenous Leukemia who have failed 2G- tyrosine kinase inhibitors (TKI)
4.6. Standard pediatric indications for myeloablative transplantation for patients
undergoing bone marrow transplant at Children's National Medical Center per
institutional guidelines
5. Disease status
If patients are found to not be in remission at screening, then the patient may be
returned to their primary hematologist/oncologist or may receive chemotherapy as per
standard of care for the malignant disease. Patients for whom this would be their
first allogeneic transplant must be in remission (< 5% malignant blasts in marrow and
peripheral blood and no evidence of extramedullary disease) for transplant. Patients
enrolled on this protocol for their second transplant do not need to have attained
remission prior to transplant.
6. Performance status: Karnofsky or Lansky performance status greater than or equal to
60% AND life expectance of greater than 3 months.
7. Ability to give informed consent. For recipients and donors < 18 years of age,
their legal guardian must give informed consent. Pediatric patients will be included
in an age appropriate discussion in accordance with institutional guidelines.
8 Hepatic function: Patients must have evidence of adequate liver function prior to
enrollment defined by total bilirubin < 2.5 mg/dL (unless documented Gilbert's
syndrome) AND transaminases less than or equal to 5 x the upper limit of normal for
age appropriate indices.
9. Renal function: Patients must have evidence of adequate renal function to proceed
with stem cell transplant, creatinine clearance > 60 ml/min/1.73 m(2). Glomerular
filtration rate (GFR) may also demonstrate adequate renal function.
10. Left ventricular ejection fraction greater than or equal to 50% OR shortening
fraction of greater than or equal to 27% demonstrated on 2-dimension (2D)
echocardiogram or multi-gated acquisition scan (MUGA).
11. Pulmonary function of Diffusing Capacity of the Lung for Carbon Monoxide (DLC0)
adj/alveolar volume (VA) and forced expiratory volume 1 (FEV1) greater than or equal
to 60% of normal indices for age and height unless the patient has a likely acute
reversible etiology of decline and then DLCO adj/VA greater than or equal to 30% of
normal. Pediatric patients unable to complete pulmonary function tests (PFTs) may be
enrolled as per enrolling institution Standard Operating Procedure (SOP) for recipient
guidelines.
12. Patients with prior autologous stem cell transplants will be included. Patients
with prior allogeneic stem cell transplants will be eligible for 2nd BMT if not
previously transplanted with FLT on this study.
13. Prior experimental systemic therapies must have been completed greater than 2
weeks prior to study entry.
EXCLUSION CRITERIA: TRANSPLANT RECIPIENT
1. History of psychiatric disorder which may compromise compliance with transplant
protocol, or which does not allow for appropriate informed consent.
2. Active infections not responding to therapy. All efforts should be made to clear
the infection prior to enrollment.
3. Clinically significant systemic illness with manifestations of significant organ
dysfunction which in the judgment principal investigator (PI) or associate
investigator (AI) would render the patient unlikely to tolerate the protocol
therapy or complete the study.
4. Presence of active malignancy from an organ system other than hematopoietic.
5. Human immunodeficiency virus (HIV) infection.
6. Chronic active hepatitis B infection. Patients may be hepatitis B core antibody
positive but must be surface antigen negative and without active evidence of
disease.
7. Pregnant or lactating females will be excluded from this trial due to unknown
risks to the developing fetus. Patients of child-bearing potential must use an
effective form of contraception while on study.
8. Sexually active individuals capable of becoming pregnant who are unable or
unwilling to use effective form(s) of contraception during time enrolled on study
and for 1 year post-transplant.
9. History of prior Leuprolide intolerance. Note: patients ARE eligible if prior or
current leuprolide exposure.
INCLUSION CRITERIA: MATCHED RELATED TRANSPLANT DONOR
1. Age greater than or equal to 2 and less than or equal to 60 years old and able to
give consent or assent. For donors < 18 years old, the legal guardian must be
able to provide informed consent and an evaluation by a Licensed Social Worker
(LSW) or psychiatric personnel will be needed to determine willingness to
participate. Pediatric patients will be included in an age appropriate discussion
in accordance with institutional guidelines.
2. Human leukocyte antigen (HLA)-matched related donor, excluding identical twins.
Donors must be matched at least 7 loci out of 8 at the allele or antigen level
excluding antigen DRB1 mismatch.
3. Donor selection will be in accordance with National Institutes of Health
(NIH)/Clinical Center (CC) Department of Transfusion Medicine criteria and must
be able to medically endure stem cell collection or as per local institutional
guidelines.
4. Donors must be HIV negative, human T-cell leukemia-lymphoma virus (HTLV)
negative, hepatitis B surface antigen (HBsA) negative.
5. Donors must be physically able to and willing to tolerate marrow harvest
collection preferably, or in the absence of this option, able and willing to
donate via peripheral blood pheresis.
EXCLUSION CRITERIA: MATCHED RELATED TRANSPLANT DONOR
1. History of medical illness that in the estimation of the PI or Department of
Transfusion Medicine (DTM) physician precludes donation of marrow.
2. Anemia (Hemoglobin (Hb) < 10 gm/dl) or thrombocytopenia (< 100,000/ ul).
3. Pregnant females (due to risk to fetus).
4. Current psychiatric diagnosis that would compromise compliance with transplant
protocol or precludes appropriate informed consent.
5. Presence of any blood transmissible infectious disease that cannot be cleared
prior to stem cell collection and poses an unacceptable risk for the recipient
(excludes cytomegalovirus (CMV)).
6. Active malignancy will exclude the donor. Any malignancy less than five years
postremission will exclude the donor. Non-hematologic malignancies greater than 5
years ago will not exclude the donor. Any history of hematologic malignancy will
be considered on a case by case basis.
7. Any medical contraindication to anesthesia or marrow donation will exclude the
donor.
8. Donors receiving experimental therapy or investigational agents.
9. Active autoimmune disease that in the opinion of the PI or AI would compromise
the success of the transplant.
INCLUSION CRITERIA- MATCHED UNRELATED DONOR
1. Unrelated donor matched at HLA-A, B, C, and DR loci by high resolution typing (at
8/8 or 7/8 antigen/allele match) are acceptable donors.
2. The evaluation of donors shall be in accordance with existing National Marrow
Donor Program (NMDP) Standard Policies and Procedures at all institutions.
INCLUSION CRITERIA- (18F) FLT CANDIDATE TRANSPLANT RECIPIENT
1. Meets criteria for Transplant Recipient
2. Age greater than or equal to 18 years old at National Cancer Institute (NCI), and
age > 4 years and < 24 years at Children's National Medical Center
3. Donor who is willing to undergo bone marrow or stem cell harvest.
EXCLUSION CRITERIA- (18F) FLT CANDIDATE TRANSPLANT RECIPIENT
1. History of prior fluorothymidine allergy or intolerance.
Maximum Eligible Age: | 55 Years |
Minimum Eligible Age: | 4 Years |
Eligible Gender: | All |
Healthy Volunteers: | No |
Primary Outcome Measures
Measure: | Percentage of B Cells at One Year Post-transplant in Participants Who Did/Did Not Receive Leuprolide Following Bone Marrow Transplant (BMT) |
Time Frame: | after first Bone Marrow Transplant, approximately 12 months post-transplant |
Safety Issue: | |
Description: | B cell percentage is defined as the percentage of lymphocytes that are B cells. |
Secondary Outcome Measures
Measure: | Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0) |
Time Frame: | Date treatment consent signed to date off study, approximately 79 months and 11 days. |
Safety Issue: | |
Description: | Here is the count of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. |
Details
Phase: | Phase 2 |
Primary Purpose: | Interventional |
Overall Status: | Completed |
Lead Sponsor: | National Cancer Institute (NCI) |
Trial Keywords
- FLT
- Leuprolide
- Thymic Renewal
- Stem Cell Transplant
- Acute Lymphocytic Leukemia
- Acute Myelogenous Leukemia
- Myelodysplastic Syndrome
Last Updated
March 18, 2021